VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Brody Discusses Exciting Therapies for Lymphomas and CLL

Joshua Brody, MD
Published: Monday, Nov 24, 2014

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).

In lymphomas and CLL, good therapies exist now, such as B-cell receptor signaling inhibitors like BTK inhibitors and PI3K inhibitors. There are also new agents, such as Bcl-2 inhibitors, that look promising.

Brody hypothesizes that some non-specific immunotherapies will likely show good results in lymphomas and CLL.

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).

In lymphomas and CLL, good therapies exist now, such as B-cell receptor signaling inhibitors like BTK inhibitors and PI3K inhibitors. There are also new agents, such as Bcl-2 inhibitors, that look promising.

Brody hypothesizes that some non-specific immunotherapies will likely show good results in lymphomas and CLL.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x